牛膝多糖对小鼠骨髓来源树突状细胞抗肿瘤能力的影响.pdfVIP

Journa l of Zhengzhou U n iv ers ity (M ed ica l Sc iences M ay 20 10 V ol. 4 5 N o. 3 359 ance: perspectives fo r mi proved drug treatm ent [ J] . D rug w ork[ J] . Curr O p in Ce ll B iol, 2005, 17( 2 : 158 R esist U pdat, 200 8, 11( 3 : 63 [ 7] P iguet A C, Sem ela D, K eogh A, et a.l Inh ib ition o f mTOR [ 2] G eorgak is GV, Y ounes A. F rom R apa N ui to rapam yc in: in comb ination w ith doxorubic in in an exper mi enta l m ode l ta rgeting P I3K /A kt/mTOR for cancer therapy[ J] . Expert o f hepatocellu lar ca rc inom a [ J] . J H epato,l 2008, 49 ( 1 : R ev A nticancer Ther, 2006, 6( 1 : 13 1 78 [ 3] Shaw R J, Cantley LC. R as, P I ( 3 K and mTOR signa ling [ 8] O R e illy K E, R ojo F, She QB, et a l. mTOR inh ib ition in con tro ls tumo r ce ll grow th [ J] . N ature, 2006, 44 1( 7 092 : duces upstream recepto r tyrosine kinase signaling and acti 424 va tes A kt[ J] . Cancer R es, 2006, 66( 3 : 1 500 [ 4] A sano T, Y ao Y, Zhu J, et al. T he rapamy cin ano log CCI [ 9] Chan S, Scheulen M E, Johnston S, et al. Phase study of 779 is a po tent inhibitor of pancreatic cancer cell pro lifera tem siro lmi us ( CC I779 , a nove l inh ib ito r o f mTOR, in tion [ J] . B iochem B iophys R es Commun, 2005, 331 ( 1 : heav ily pretreated patients w ith locally advanced or m eta 295 sta tic breast cancer[ J] . J C lin O ncol, 2005, 23( 23 : 5 314 [ 5] D ong M, N io Y, Sato Y, et a.l Comparative study o f p53 ex [ 10] G a lan is E, Buckner JC, M aurer M J, et al. P hase tr ia l of pression in pr mi ary invasive ducta l carc inom a of the pan tem siro lmi us ( CC I779 in recurrent g lioblastom a mu lti creas betw een Ch inese and J apanese [ J] . P a